Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 4, 2012, Pages 487-491

  Martinotti, Giovanni ^a   Sepede, Gianna ^a   Gambi, Francesco ^a   Di Iorio, Giuseppe ^a   De Berardis, Domenico ^c   Di Nicola, Marco ^b   Onofrj, Marco ^a   Janiri, Luigi ^b   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c National Health Trust   (Italy)

Author keywords

Agomelatine; Anhedonia; Major depressive disorder; Venlafaxine

Indexed keywords

AGOMELATINE; VENLAFAXINE;

ADULT; ANHEDONIA; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONFUSION; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA AND VOMITING; OPEN STUDY; PARALLEL DESIGN; PILOT STUDY; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY;

ACETAMIDES; ADOLESCENT; ADULT; ANHEDONIA; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PATIENT DROPOUTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84863717569     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31825d6c25     Document Type: Article

References (35)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva, Switzerland: World Health Organization; 2008:43-51.
2. Spijker J, Bijl RV, de Graaf R, et al. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand. 2001;103:122-130. (Pubitemid 32147133)
3. Taylor DJ, Walters HM, Vittengl JR, et al. Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence? J Affect Disord. 2010;123:181-187.
4. Keedwell PA, Andrew C, Williams SC, et al. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry. 2005;58:843-853. (Pubitemid 41790711)
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917. (Pubitemid 44807782)
6. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105. (Pubitemid 37432885)
7. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42:1822-1831.
8. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem. 1992;35: 1484-1486.
9. Papp M, Gruca P, Boyer PA, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology. 2003;28:694-703.
10. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther. 2006;110:135-370.
11. Lôo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
12. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93-100. (Pubitemid 43145814)
13. Olié JP, Kasper S. Efficacy of agomelatine, an MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661-673. (Pubitemid 47517525)
14. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2010;30:135-144.
15. Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2011;12:2411-2419.
16. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011;25:109-114.
17. De Berardis D, Di Iorio G, Acciavatti T, et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011;10:119-132.
18. Sapetti A. Agomelatine: an antidepressant without deterioration of sexual response. J Sex Marital Ther. 2012;38:190-197.
19. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271-280. (Pubitemid 39141943)
20. Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol. 2006;21:25-29.
21. Kupfer DJ. Depression and associated sleep disturbances: patient benefit with agomelatine. Eur Neuropsychopharmacol. 2006;16(suppl 5): 639-643.
22. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone: the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99-103. (Pubitemid 26124582)
23. Hamilton M. The assessment of anxiety states by rating. Brit J Med Psychol. 1959;32:50-55.
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
25. Mann JJ. The medical management of depression. N Engl J Med. 2005;353:1819-1834.
26. Ribot T. La Psychologie Des Sentiments. Paris, France: Felix Alcan; 1896.
27. Loas G, Pierson A. Anhedonia in psychiatry: a review. Ann Med Psychol. 1989;147:705-717.
28. Meehl PE. Hedonic capacity: some conjectures. Bull Menninger Clin. 1975;39:295-307.
29. Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs naltrexone. J Psychopharmacol. 2009;23:123-129.
30. Martinotti G, Andreoli S, Reina D, et al. Acetyl-L-carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):953-958.
31. Martinotti G, Di Nicola M, Reina D, et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse. 2008;43:271-284. (Pubitemid 351448715)
32. Farina B, Della Marca G, Mennuni G, et al. The effects of reboxetine on human sleep architecture in depression: preliminary results. J Affect Disord. 2002;71:273-275.
33. Coogan AN, Thome J. Chronotherapeutics and psychiatry: setting the clock to relieve the symptoms. World J Biol Psychiatry. 2011;12:40-43.
34. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28(3):329-333.
35. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68(11):1723-1732. (Pubitemid 350247502)